Niagen Bioscience Inc (NAGE) Stock

Understand Niagen Bioscience Inc: how it makes money

Niagen Bioscience researches nicotinamide adenine dinucleotide (NAD) for healthy aging and earns sales primarily from Tru Niagen products and Niagen ingredient sales, including distribution through retail and business-to-business partners.

The company’s profitability appears driven by keeping operating costs controlled while scaling sales across its high-level revenue streams (Tru Niagen product sales and Niagen ingredient sales), supported by a reported high gross margin (63.5%) but a much lower operating margin (5.0).

Business quality (Mixed): Clear operating drivers are available through retail and clinic distribution metrics, but reported revenue is very small in this dataset, which can make quarterly performance and segment visibility harder to interpret.

Valuation: At 16× earnings, NAGE trades in line with the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

• Gross margin cushion: Reported gross margin is 63.5%, which can support profitability if the company scales sales without proportionally increasing operating costs.
• Multiple monetization channels: Revenue candidates indicate both Tru Niagen net sales and Niagen ingredient net sales, with business-to-business distribution partner revenue also present.
• Retail and clinic footprint signals distribution reach: The dataset shows iHerb Active Subscribers (10,000,000) and Number of Clinics (1,200), both pointing to ongoing distribution access.

Bear case

• Operating leverage risk: The gap between gross margin (63.5%) and operating margin (5.0%) suggests operating expenses are a key constraint on earnings power.
• Small revenue base in the reported quarter: Net sales and segment revenues are very low in this dataset (Net Sales 0.03B), which can make results more sensitive to execution and demand changes.
• Some revenue streams appear immaterial: Watson Revenue is shown as 0.0B in the candidates provided, implying limited contribution from that line in the latest quarter data.

Related Companies (Business model: Branded Consumer (CPG, Staples, Beauty, Alcohol, Pet, Nicotine); 8 closest by market cap; US-domiciled)

• Definium Therapeutics, Inc. (DFTX)
• Edgewell Personal Care Company (EPC)
• USANA Health Sciences, Inc. (USNA)
• Waldencast plc (WALD)
• FitLife Brands, Inc. (FTLF)
• Solesence, Inc. Common Stock (SLSN)
• biote Corp. (BTMD)
• Natural Alternatives International, Inc. (NAII)